Ratings by BofA Securities (Tazeen Ahmad)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/22/2026 | Taysha Gene Therapies | TSHA | Maintain | Buy (N/A) |
|
Details | ||
| 6/18/2026 | Immix Biopharma, Inc. | IMMX | New Coverage | Buy (N/A) |
9.13 (10.49) |
14.9% | Details | |
| 5/20/2026 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2026 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2026 | Arvinas Inc. | ARVN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2026 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2026 | Alto Neuroscience | ANRO | New Coverage | Buy (N/A) |
24.94 (28.07) |
12.55% | Details | |
| 5/1/2026 | Amgen | AMGN | Maintain | Underperform (N/A) |
|
Details | ||
| 4/15/2026 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2026 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2026 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Underperform (N/A) |
|
Details | ||
| 3/25/2026 | Acadia Pharmaceuticals | ACAD | Upgrade | Buy (Neutral) |
20.96 (25.20) |
20.23% | Details | |
| 3/24/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 3/23/2026 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2026 | Sarepta Therapeutics | SRPT | Maintain | Underperform (N/A) |
|
Details | ||
| 3/12/2026 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2026 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2026 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2026 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2026 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2026 | Fulcrum Therapeutics | FULC | Maintain | Underperform (N/A) |
|
Details | ||
| 2/20/2026 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 2/12/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2026 | Amgen | AMGN | Maintain | Underperform (N/A) |
|
Details | ||
| 1/21/2026 | Apellis Pharmaceuticals | APLS | Upgrade | Buy (Neutral) |
20.47 (41.03) |
100.44% | Details | |
| 1/12/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2026 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 12/18/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2025 | Fulcrum Therapeutics | FULC | Maintain | Underperform (N/A) |
|
Details | ||
| 12/8/2025 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Pharvaris B.V. | PHVS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2025 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2025 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2025 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/9/2025 | Scholar Rock | SRRK | New Coverage | Buy (N/A) |
38.69 (54.96) |
42.05% | Details | |
| 10/9/2025 | Pharvaris B.V. | PHVS | Upgrade | Neutral (Underperform) |
22.44 (34.71) |
54.68% | Details | |
| 10/6/2025 | Arvinas Inc. | ARVN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/24/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 9/24/2025 | Arvinas Inc. | ARVN | Downgrade | Neutral (Buy) |
7.53 (8.29) |
10.09% | Details | |
| 9/12/2025 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 9/11/2025 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2025 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2025 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2025 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 8/21/2025 | Sarepta Therapeutics | SRPT | Maintain | Underperform (N/A) |
|
Details | ||
| 8/19/2025 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2025 | Sarepta Therapeutics | SRPT | Downgrade | Underperform (Neutral) |
13.61 (17.02) |
25.06% | Details | |
| 7/21/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/15/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 7/15/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 7/11/2025 | Taysha Gene Therapies | TSHA | New Coverage | Buy (N/A) |
2.55 (6.73) |
163.92% | Details | |
| 7/10/2025 | Pharvaris B.V. | PHVS | Maintain | Underperform (N/A) |
|
Details | ||
| 7/10/2025 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 7/9/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2025 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2025 | Sarepta Therapeutics | SRPT | Downgrade | Neutral (Buy) |
36.18 (13.61) |
-62.38% | Details | |
| 6/11/2025 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 6/9/2025 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2025 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 6/4/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 6/2/2025 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 5/28/2025 | Prothena Corp | PRTA | Downgrade | Underperform (Neutral) |
4.58 (9.97) |
117.69% | Details | |
| 5/9/2025 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Buy) |
17.99 (20.47) |
13.79% | Details | |
| 5/9/2025 | PTC Therapeutics | PTCT | Upgrade | Buy (Neutral) |
55.00 (81.57) |
48.31% | Details | |
| 5/5/2025 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2025 | Incyte | incy | Maintain | Buy (N/A) |
|
Details | ||
| 4/7/2025 | Rhythm Pharmaceuticals | RYTM | Upgrade | Buy (Neutral) |
46.95 (110.04) |
134.38% | Details | |
| 3/31/2025 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2025 | Sutro Biopharma | STRO | Downgrade | Underperform (Buy) |
1.25 (33.35) |
2568% | Details | |
| 3/11/2025 | PTC Therapeutics | PTCT | Upgrade | Neutral (Underperform) |
52.49 (55.00) |
4.78% | Details | |
| 3/11/2025 | Sage Therapeutics | SAGE | New Coverage | Underperform (N/A) |
7.50 (8.68) |
15.73% | Details | |
| 3/10/2025 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2025 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2025 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/10/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2025 | Ocular Therapeutix | OCUL | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2025 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 2/13/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2025 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2024 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2024 | Prothena Corp | PRTA | Maintain | Neutral (N/A) |
|
Details | ||
| 12/18/2024 | Kalvista Pharmaceuticals Inc | KALV | New Coverage | Buy (N/A) |
8.65 (27.00) |
212.14% | Details | |
| 12/17/2024 | Annexon Biosciences | ANNX | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2024 | PepGen Inc. | PEPG | Downgrade | Underperform (Neutral) |
4.68 (1.78) |
-61.97% | Details | |
| 11/18/2024 | Fate Therapeutics | FATE | Upgrade | Neutral (Underperform) |
2.02 (2.42) |
19.8% | Details | |
| 11/18/2024 | PepGen Inc. | PEPG | Maintain | Neutral (N/A) |
|
Details | ||
| 11/12/2024 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2024 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 11/4/2024 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2024 | Incyte | INCY | Upgrade | Buy (Buy) |
65.69 (114.66) |
74.55% | Details | |
| 10/17/2024 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2024 | Sutro Biopharma | STRO | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2024 | Prothena Corp | PRTA | Maintain | Neutral (N/A) |
|
Details | ||
| 9/27/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2024 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/16/2024 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2024 | Fulcrum Therapeutics | FULC | Downgrade | Underperform (Neutral) |
8.85 (3.73) |
-57.85% | Details | |
| 9/9/2024 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2024 | Fulcrum Therapeutics | FULC | Upgrade | Neutral (Underperform) |
8.54 (3.73) |
-56.32% | Details | |
| 9/4/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 6/21/2024 | PTC Therapeutics | PTCT | Maintain | Underperform (N/A) |
|
Details | ||
| 6/21/2024 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 6/12/2024 | Sage Therapeutics | SAGE | Maintain | Underperform (N/A) |
|
Details | ||
| 6/12/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 6/5/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2024 | Fulcrum Therapeutics | FULC | Maintain | Underperform (N/A) |
|
Details | ||
| 5/10/2024 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/8/2024 | Rhythm Pharmaceuticals | RYTM | Downgrade | Neutral (Buy) |
39.35 (110.04) |
179.64% | Details | |
| 5/8/2024 | Sutro Biopharma | STRO | New Coverage | Buy (N/A) |
4.25 (1.25) |
-70.59% | Details | |
| 4/24/2024 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/17/2024 | Sage Therapeutics | SAGE | Downgrade | Underperform (Neutral) |
15.63 (8.68) |
-44.47% | Details | |
| 4/12/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/12/2024 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2024 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/12/2024 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2024 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 4/9/2024 | Inozyme Pharma Inc. | INZY | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2024 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/12/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2024 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/9/2024 | Ocular Therapeutix | OCUL | New Coverage | Buy (N/A) |
5.03 (9.90) |
96.82% | Details | |
| 1/30/2024 | Prothena Corp | PRTA | Downgrade | Neutral (Buy) |
33.76 (4.58) |
-86.43% | Details | |
| 1/22/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 1/17/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/12/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2024 | Cyteir Therapeutics | CYT | Downgrade | Underperform (Neutral) |
3.06 (3.02) |
-1.31% | Details | |
| 12/21/2023 | Annexon Biosciences | ANNX | Upgrade | Buy (Neutral) |
2.88 (5.57) |
93.4% | Details | |
| 12/14/2023 | Achilles Therapeutics | ACHL | Downgrade | Underperform (Buy) |
0.96 (1.48) |
54.17% | Details | |
| 12/7/2023 | Pharvaris B.V. | PHVS | Maintain | Underperform (N/A) |
|
Details | ||
| 12/5/2023 | Apellis Pharmaceuticals | APLS | Upgrade | Buy (Neutral) |
61.58 (41.03) |
-33.37% | Details | |
| 11/2/2023 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/24/2023 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2023 | PTC Therapeutics | PTCT | Maintain | Underperform (N/A) |
|
Details | ||
| 10/17/2023 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 10/17/2023 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2023 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2023 | ADC Therapeutics | ADCT | Maintain | Underperform (N/A) |
|
Details | ||
| 10/17/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 10/12/2023 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 9/19/2023 | PTC Therapeutics | PTCT | Maintain | Underperform (N/A) |
|
Details | ||
| 9/8/2023 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 9/8/2023 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/23/2023 | Fulcrum Therapeutics | FULC | Maintain | Underperform (N/A) |
|
Details | ||
| 8/7/2023 | Sage Therapeutics | SAGE | Downgrade | Neutral (Buy) |
36.10 (8.68) |
-75.96% | Details | |
| 8/3/2023 | Cerevel Therapeutics | CERE | Downgrade | Neutral (Buy) |
26.33 (44.96) |
70.76% | Details | |
| 8/1/2023 | Rhythm Pharmaceuticals | RYTM | Upgrade | Buy (Neutral) |
17.84 (110.04) |
516.82% | Details | |
| 8/1/2023 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Buy) |
0.00 (41.03) |
0% | Details | |
| 8/1/2023 | Annexon Biosciences | ANNX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/18/2023 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2023 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 6/8/2023 | 4D Molecular Therapeutics | FDMT | Maintain | Buy (N/A) |
|
Details | ||
| 5/26/2023 | Annexon Biosciences | ANNX | Downgrade | Neutral (Buy) |
2.10 (5.57) |
165.24% | Details | |
| 5/22/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/15/2023 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2023 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2023 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Prothena Corp | PRTA | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2023 | Incyte | INCY | Downgrade | Neutral (Buy) |
68.04 (65.69) |
-3.45% | Details | |
| 5/3/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Neutral (N/A) |
|
Details | ||
| 5/3/2023 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 4/24/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Neutral (N/A) |
|
Details | ||
| 4/24/2023 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 4/24/2023 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 4/24/2023 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 4/24/2023 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/24/2023 | ADC Therapeutics | ADCT | Downgrade | Underperform (Neutral) |
2.30 (1.03) |
-55.22% | Details | |
| 3/28/2023 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2023 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2023 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2023 | Praxis Precision Medicines Inc. | PRAX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/7/2023 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2023 | Fulcrum Therapeutics | FULC | Downgrade | Underperform (Neutral) |
12.89 (3.73) |
-71.06% | Details | |
| 2/21/2023 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 2/16/2023 | Galera Therapeutics | GRTX | Upgrade | Buy (Underperform) |
1.66 (0.15) |
-90.96% | Details | |
| 2/7/2023 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2023 | Cyteir Therapeutics | CYT | Downgrade | Neutral (Buy) |
1.71 (3.02) |
76.61% | Details | |
| 1/10/2023 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2023 | Fate Therapeutics | FATE | Downgrade | Underperform (Buy) |
11.00 (2.42) |
-78% | Details | |
| 1/4/2023 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 1/4/2023 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2022 | BioNTech | BNTX | Upgrade | Buy (Neutral) |
186.05 (94.26) |
-49.34% | Details | |
| 12/13/2022 | 4D Molecular Therapeutics | FDMT | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Neutral (N/A) |
|
Details | ||
| 12/9/2022 | Pharvaris B.V. | PHVS | Maintain | Underperform (N/A) |
|
Details | ||
| 12/5/2022 | Prothena Corp | PRTA | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2022 | SQZ Biotechnologies | SQZ | Downgrade | Underperform (Buy) |
2.51 (0.44) |
-82.47% | Details | |
| 11/29/2022 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 11/21/2022 | Prelude Therapeutics | PRLD | Downgrade | Underperform (Neutral) |
7.44 (4.93) |
-33.74% | Details | |
| 11/17/2022 | Surrozen Inc. | SRZN | Downgrade | Underperform (Neutral) |
1.25 (25.72) |
1957.6% | Details | |
| 11/9/2022 | ADC Therapeutics | ADCT | Downgrade | Neutral (Buy) |
4.26 (1.03) |
-75.82% | Details | |
| 11/8/2022 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 11/4/2022 | Fate Therapeutics | FATE | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2022 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2022 | Cerevel Therapeutics | CERE | New Coverage | Buy (N/A) |
25.75 (44.96) |
74.6% | Details | |
| 9/28/2022 | Prothena Corp | PRTA | Upgrade | Buy (Neutral) |
30.93 (9.97) |
-67.77% | Details | |
| 8/24/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Neutral (N/A) |
|
Details | ||
| 8/22/2022 | Pharvaris B.V. | PHVS | Downgrade | Underperform (Neutral) |
18.49 (22.44) |
21.36% | Details | |
| 8/18/2022 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2022 | Praxis Precision Medicines Inc. | PRAX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/18/2022 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2022 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2022 | Rhythm Pharmaceuticals | RYTM | Upgrade | Neutral (Underperform) |
18.59 (110.04) |
491.93% | Details | |
| 7/20/2022 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 6/15/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 6/15/2022 | Fulcrum Therapeutics | FULC | Maintain | Neutral (N/A) |
|
Details | ||
| 6/8/2022 | Annexon Biosciences | ANNX | Maintain | Buy (N/A) |
|
Details | ||
| 6/7/2022 | Praxis Precision Medicines Inc. | PRAX | Downgrade | Neutral (Buy) |
1.88 (350.56) |
18546.81% | Details | |
| 5/31/2022 | PepGen Inc. | PEPG | New Coverage | Buy (N/A) |
10.88 (4.68) |
-56.99% | Details | |
| 5/27/2022 | Surrozen Inc. | SRZN | Downgrade | Neutral (Buy) |
2.55 (25.72) |
908.63% | Details | |
| 5/27/2022 | Molecular Templates | MTEM | Downgrade | Underperform (Buy) |
0.97 (0.11) |
-88.66% | Details | |
| 5/27/2022 | Galera Therapeutics | GRTX | Downgrade | Underperform (Neutral) |
1.74 (0.15) |
-91.38% | Details | |
| 5/24/2022 | PTC Therapeutics | PTCT | Maintain | Underperform (N/A) |
|
Details | ||
| 4/19/2022 | Theravance Biopharma | TBPH | Maintain | Underperform (N/A) |
|
Details | ||
| 4/19/2022 | PTC Therapeutics | PTCT | Maintain | Underperform (N/A) |
|
Details | ||
| 4/19/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/19/2022 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2022 | Ascendis Pharma | ASND | Maintain | Neutral (N/A) |
|
Details | ||
| 4/19/2022 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2022 | ADC Therapeutics | ADCT | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2022 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2022 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 4/8/2022 | VectivBio Holding AG | VECT | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/18/2022 | SQZ Biotechnologies | SQZ | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2022 | Inozyme Pharma Inc. | INZY | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2022 | Ascendis Pharma | ASND | Upgrade | Buy (Neutral) |
102.64 (263.70) |
156.92% | Details | |
| 3/15/2022 | Prelude Therapeutics | PRLD | Downgrade | Neutral (Buy) |
7.75 (4.93) |
-36.39% | Details | |
| 3/3/2022 | Fulcrum Therapeutics | FULC | Upgrade | Neutral (Underperform) |
11.10 (3.73) |
-66.4% | Details | |
| 3/3/2022 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2022 | Ascendis Pharma | ASND | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2022 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Underperform (N/A) |
|
Details | ||
| 2/9/2022 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2022 | Cortexyme Inc. | CRTX | Maintain | Underperform (N/A) |
|
Details | ||
| 1/26/2022 | Theravance Biopharma | TBPH | Maintain | Underperform (N/A) |
|
Details | ||
| 1/26/2022 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2022 | Rhythm Pharmaceuticals | RYTM | Maintain | Underperform (N/A) |
|
Details | ||
| 1/26/2022 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2022 | Prothena Corp | PRTA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/26/2022 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2022 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2022 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2022 | Clovis Oncology | CLVS | Maintain | Underperform (N/A) |
|
Details | ||
| 1/26/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/26/2022 | Ascendis Pharma | ASND | Maintain | Neutral (N/A) |
|
Details | ||
| 1/26/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2022 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 1/12/2022 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 12/14/2021 | Galera Therapeutics | GRTX | Upgrade | Neutral (Underperform) |
1.38 (0.15) |
-89.13% | Details | |
| 12/13/2021 | Prelude Therapeutics | PRLD | Maintain | Buy (N/A) |
|
Details | ||
| 12/6/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2021 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2021 | Pyxis Oncology Inc. | PYXS | New Coverage | Neutral (N/A) |
13.20 (2.86) |
-78.33% | Details | |
| 10/29/2021 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 10/27/2021 | Cortexyme Inc. | CRTX | Downgrade | Underperform (Neutral) |
57.68 (1.95) |
-96.62% | Details | |
| 10/21/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/21/2021 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2021 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2021 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2021 | Ascendis Pharma | ASND | Downgrade | Neutral (Buy) |
153.49 (263.70) |
71.8% | Details | |
| 10/19/2021 | Galera Therapeutics | GRTX | Downgrade | Underperform (Buy) |
7.40 (1.38) |
-81.35% | Details | |
| 10/18/2021 | PTC Therapeutics | PTCT | Downgrade | Underperform (Neutral) |
38.09 (52.49) |
37.81% | Details | |
| 10/11/2021 | Surrozen Inc. | SRZN | New Coverage | Buy (N/A) |
6.39 (25.72) |
302.5% | Details | |
| 9/24/2021 | Fulcrum Therapeutics | FULC | Maintain | Underperform (N/A) |
|
Details | ||
| 9/23/2021 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 8/24/2021 | Theravance Biopharma | TBPH | Maintain | Underperform (N/A) |
|
Details | ||
| 8/11/2021 | Fulcrum Therapeutics | FULC | Maintain | Underperform (N/A) |
|
Details | ||
| 8/11/2021 | Achilles Therapeutics | ACHL | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2021 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2021 | SQZ Biotechnologies | SQZ | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2021 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2021 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2021 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2021 | ADC Therapeutics | ADCT | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2021 | Rhythm Pharmaceuticals | RYTM | Downgrade | Underperform (Neutral) |
16.63 (110.04) |
561.7% | Details | |
| 8/4/2021 | Pharvaris B.V. | PHVS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/3/2021 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 7/27/2021 | Prelude Therapeutics | PRLD | Upgrade | Buy (Neutral) |
33.33 (4.93) |
-85.21% | Details | |
| 7/21/2021 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 7/21/2021 | Kala Pharmaceuticals | KALA | Maintain | Buy (N/A) |
|
Details | ||
| 7/21/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 7/13/2021 | Ambrx Biopharma | AMAM | New Coverage | Buy (N/A) |
21.30 (28.00) |
31.46% | Details | |
| 7/13/2021 | Cyteir Therapeutics | CYT | New Coverage | Buy (N/A) |
19.65 (3.02) |
-84.63% | Details | |
| 6/29/2021 | Ultragenyx Pharma | RARE | Upgrade | Buy (Neutral) |
96.40 (30.68) |
-68.17% | Details | |
| 6/16/2021 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2021 | Rhythm Pharmaceuticals | RYTM | Maintain | Neutral (N/A) |
|
Details | ||
| 4/19/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/10/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Neutral (Buy) |
25.02 (25.43) |
1.64% | Details | |
| 3/9/2021 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 2/12/2021 | PTC Therapeutics | PTCT | Downgrade | Neutral (Buy) |
63.27 (81.57) |
28.92% | Details | |
| 2/12/2021 | Ultragenyx Pharma | RARE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/12/2021 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2021 | Rhythm Pharmaceuticals | RYTM | Maintain | Neutral (N/A) |
|
Details | ||
| 1/13/2021 | Ultragenyx Pharma | RARE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/18/2020 | Amicus Therapeutics | FOLD | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2020 | BioNTech | BNTX | Downgrade | Neutral (Buy) |
109.99 (94.26) |
-14.3% | Details | |
| 11/24/2020 | SQZ Biotechnologies | SQZ | New Coverage | Buy (N/A) |
27.62 (0.44) |
-98.41% | Details | |
| 11/20/2020 | Prelude Therapeutics | PRLD | Downgrade | Neutral (Buy) |
54.95 (4.93) |
-91.03% | Details | |
| 11/12/2020 | Ultragenyx Pharma | RARE | Downgrade | Neutral (Buy) |
117.48 (30.68) |
-73.88% | Details | |
| 11/10/2020 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/27/2020 | Galera Therapeutics | GRTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2020 | Prelude Therapeutics | PRLD | New Coverage | Buy (N/A) |
32.69 (4.93) |
-84.92% | Details | |
| 10/15/2020 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2020 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2020 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 9/14/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 8/21/2020 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2020 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2020 | Zogenix, Inc. | ZGNX | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2020 | Immunomedics | IMMU | Maintain | Buy (N/A) |
|
Details | ||
| 6/24/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 6/11/2020 | Kala Pharmaceuticals | KALA | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2020 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 5/27/2020 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 5/27/2020 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2020 | GW Pharma | GWPH | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 4/8/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 4/7/2020 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2020 | GW Pharma | GWPH | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2020 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2020 | Cortexyme Inc. | CRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/18/2020 | Kala Pharmaceuticals | KALA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/18/2020 | Galera Therapeutics | GRTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2020 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2020 | 89bio Inc. | ETNB | Maintain | Neutral (N/A) |
|
Details | ||
| 2/18/2020 | MyoKardia | MYOK | Maintain | Buy (N/A) |
|
Details | ||
| 1/23/2020 | Clovis Oncology | CLVS | Maintain | Neutral (N/A) |
|
Details | ||
| 1/23/2020 | Fulcrrum Therapeutics | FULC | Maintain | Buy (N/A) |
|
Details | ||
| 1/23/2020 | Principia Biopharma | PRNB | Maintain | Buy (N/A) |
|
Details | ||
| 1/14/2020 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 1/14/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 1/14/2020 | Neurocrine Bio. | NBIX | Maintain | Buy (N/A) |
|
Details | ||
| 1/14/2020 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2020 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2019 | 89bio Inc. | ETNB | New Coverage | Neutral (N/A) |
28.60 (14.84) |
-48.11% | Details | |
| 11/26/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 11/21/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2019 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
90.85 (293.52) |
223.08% | Details | |
| 8/26/2019 | The Medicines Company | MDCO | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 7/15/2019 | Prevail Therapeutics | PRVL | New Coverage | Buy (N/A) |
12.13 (23.00) |
89.61% | Details | |
| 6/21/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2019 | PTC Therapeutics | PTCT | Upgrade | Buy (Neutral) |
40.53 (63.27) |
56.11% | Details | |
| 5/7/2019 | GW Pharma | GWPH | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2018 | DBV Technologies S.A | DBVT | Downgrade | Underperform (Buy) |
14.15 (16.00) |
13.07% | Details | |
| 11/28/2018 | GW Pharma | GWPH | Maintain | Buy (N/A) |
|
Details | ||
| 11/12/2018 | Tesaro | TSRO | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2018 | Seattle Genetics | SGEN | Downgrade | Underperform (Neutral) |
65.35 (117.08) |
79.16% | Details | |
| 10/9/2018 | Principia Biopharma | PRNB | Upgrade | Buy (N/A) |
26.37 (100.05) |
279.41% | Details | |
| 10/5/2018 | Adamas Pharmaceuticals | ADMS | Downgrade | Neutral (Buy) |
19.98 (6.67) |
-66.62% | Details | |
| 10/3/2018 | PTC Therapeutics | PTCT | Upgrade | Neutral (Underperform) |
45.28 (40.53) |
-10.49% | Details | |
| 9/28/2018 | GW Pharma | GWPH | Maintain | Buy (Buy) |
|
Details | ||
| 9/21/2018 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 9/14/2018 | Zogenix, Inc. | ZGNX | New Coverage | Buy (N/A) |
48.25 (26.68) |
-44.7% | Details | |
| 9/14/2018 | Sarepta Therapeutics | SRPT | New Coverage | Buy (N/A) |
150.77 (36.18) |
-76% | Details |
